Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib and Palbociclib in Previously Treated Mantle Cell Lymphoma
NCT02159755Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2014
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ibrutinib and palbociclib in mantle cell lymphoma (MCL), sponsored by National Cancer Institute. Primary endpoint: Recommended Phase II Dose at 28 days. Started Aug 2014; status: active, not recruiting.
02
Drugs
ibrutinibpalbociclib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02159755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02159755.